|
(Health-NewsWire.Net, November 26, 2015 ) GAD is a common mental illness that is characterized by persistent and unrelenting worrying about everyday things such as personal finances, health, family, and work. GAD can be accompanied by one or all of the following physical symptoms: headache, fatigue, restlessness, edginess, and increased irritability. GAD is only diagnosed if the patients worrying and anxiety present most days out of a week for at least six months in combination with one or more of the physical symptoms. The diagnosis of GAD must also be shown not to be directly related to any substance abuse disorder or general medical condition; it must not occur exclusively during an episodic mood disorder, psychotic disorder, or pervasive developmental disorder.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=466522
GlobalData epidemiologists forecast that the 12-month total prevalent cases of GAD in the 8MM will grow by 4.8% from 13,688,954 cases in 2014 to 14,349,464 in 2024 and lifetime total prevalence will grow by 4.8% from 24,594,259 cases in 2014 to 25,770,599 in 2024. GlobalData epidemiologists predict that GAD will affect more women than men with 69.35% of 12-month GAD and 66.04% of lifetime GAD found in women in 2014. GlobalData epidemiologists forecast that the prevalence of 12-month and lifetime GAD peaks in the age group 5059 years, which contributed 23.57% of 12-month GAD and 23.54% of lifetime GAD in the 8MM in 2014.
GlobalDatas epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of GAD in the 8MM during 20142024. GlobalDatas epidemiological forecast for the 12-month and lifetime total prevalent cases of GAD in the 8MM is supported by epidemiological data from country-specific studies, when available, which are nationally representative of the entire population of the respective market. This forecast is further strengthened by the use of uniform diagnostic criteria and methodology across each study that was included in the forecast. All countries for which data was found used the DSM-IV diagnostic criteria as well as the CIDI to estimate the total prevalence of GAD in each country. Each study used also presented a total prevalence rather than diagnosed, which gives a better estimate of the true burden of the disease as it will catch the undiagnosed cases of the disease.
Scope
- The Generalized Anxiety Disorder (GAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for GAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast of the one-year and lifetime prevalent cases of GAD segmented by sex, and age (in five-year increments beginning at 18 years and ending at =85 years) in these markets.
- The GAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.
Reasons to buy
The GAD EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global GAD market.
- Quantify patient populations in the global GAD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for GAD therapeutics in each of the markets covered.
Browse Detail Report With TOC @ http://www.researchmoz.us/epicast-report-generalized-anxiety-disorder-epidemiology-forecast-to-2024-report.html
Table of Contents
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 7
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 11
3.4 Forecast Methodology 12
3.4.1 Sources Used 13
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods 17
3.5 Epidemiological Forecast of 12-Month Total Prevalent Cases of GAD (2014-2024) 19
3.5.1 12-Month Total Prevalent Cases of GAD 19
3.5.2 Age-Specific 12-Month Total Prevalent Cases 21
3.5.3 Sex-Specific 12- Month Total Prevalent Cases 23
3.5.4 Age-Standardized 12-Month Total Prevalent Cases 25
3.6 Epidemiological Forecast of Lifetime Total Prevalent Cases of GAD (2012-2014) 26
3.6.1 Lifetime Total Prevalent Cases of GAD 26
3.6.2 Age-Specific Lifetime Total Prevalent Cases of GAD 28
3.6.3 Sex-Specific Lifetime Total Prevalent Cases of GAD 30
3.6.4 Age-Standardized Lifetime Prevalence of GAD 32
3.7 Discussion 33
3.7.1 Epidemiological Forecast Insight 33
3.7.2 Limitations of the Analysis 34
3.7.3 Strengths of the Analysis 35
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 39
4.2.1 Epidemiologists 39
4.2.2 Reviewers 39
4.2.3 Global Director of Therapy Analysis and Epidemiology 40
4.2.4 Global Head of Healthcare 41
4.3 About GlobalData 42
4.4 About EpiCast 42
4.5 Disclaimer 43
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=466522
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
